Amedeo Smart

Free Medical Literature Service



Autoimmune Disorders

  Free Subscription

Articles published in
Ann Neurol
    June 2023
  1. PITTOCK SJ, Barnett M, Bennett JL, Berthele A, et al
    Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Ann Neurol. 2023;93:1053-1068.
    >> Share

  2. YIN HX, Wang YJ, Liu MG, Zhang DD, et al
    Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.
    Ann Neurol. 2023;93:1069-1081.
    >> Share

    May 2023
  3. HOLM HANSEN R, von Essen MR, Mahler MR, Cobanovic S, et al
    Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
    Ann Neurol. 2023 May 16. doi: 10.1002/ana.26684.
    >> Share

  4. PATRICK MT, Nair RP, He K, Stuart PE, et al
    Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.
    Ann Neurol. 2023 May 1. doi: 10.1002/ana.26672.
    >> Share

    April 2023
  5. HAMZAOUI M, Garcia J, Boffa G, Lazzarotto A, et al
    Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
    Ann Neurol. 2023 Apr 11. doi: 10.1002/ana.26657.
    >> Share

    March 2023
  6. BAKIRTZIS C, Langdon DW, Grigoriadis N
    Time to rebaseline cognitive performance in people with multiple sclerosis?
    Ann Neurol. 2023 Mar 8. doi: 10.1002/ana.26628.
    >> Share

  7. GALARDI MM, Sowa GM, Crockett CD, Rudock R, et al
    Pathogen and Antibody Identification in Children with Encephalitis in Myanmar.
    Ann Neurol. 2023;93:615-628.
    >> Share

    February 2023
  8. KALLURI HV, Rosebraugh MR, Misko TP, Ziemann A, et al
    Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.
    Ann Neurol. 2023;93:285-296.
    >> Share

    January 2023
  9. SALVARANI C, Paludo J, Hunder GG, Ansell SM, et al
    Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis.
    Ann Neurol. 2023;93:120-130.
    >> Share

  10. STREDNY CM, Blessing MM, Yi V, Ryan ME, et al
    Mimics of Pediatric Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2023;93:109-119.
    >> Share

    December 2022
  11. PAYET CA, You A, Fayet OM, Hemery E, et al
    Central role of macrophages and nucleic acid release in Myasthenia Gravis thymus.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26590.
    >> Share

  12. VAN DEN BOSCH AMR, Hummert S, Steyer A, Ruhwedel T, et al
    Ultrastructural Axon-Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation.
    Ann Neurol. 2022 Dec 24. doi: 10.1002/ana.26585.
    >> Share

  13. ZHANG Y, Zhou Q, Peng L, Chen S, et al
    Increased cerebellum (18) F-DPA-714 uptake in anti-Gluk2-autoimmune encephalitis.
    Ann Neurol. 2022 Dec 8. doi: 10.1002/ana.26563.
    >> Share

  14. NGUYEN S, Bastien E, Chretien B, Sassier M, et al
    Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Ann Neurol. 2022;92:1080-1089.
    >> Share

    November 2022
  15. OKUDA DT, Kantarci O, Lebrun-Frenay C, Sormani MP, et al
    Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome.
    Ann Neurol. 2022 Nov 18. doi: 10.1002/ana.26555.
    >> Share

  16. GARCIA-MONTOJO M, Simula ER, Fathi S, McMahan C, et al
    Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:782-792.
    >> Share

    October 2022
  17. VAN KEMPEN ZLE, Hogenboom L, Toorop AA, Steenhuis M, et al
    Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis.
    Ann Neurol. 2022 Oct 17. doi: 10.1002/ana.26534.
    >> Share

  18. MURPHY OC, Sotirchos ES, Kalaitzidis G, Vasileiou E, et al
    Trans-synaptic degeneration following acute optic neuritis in multiple sclerosis.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26529.
    >> Share

    September 2022
  19. KELLER CW, Chuquisana O, Derdelinckx J, Gross CC, et al
    Impaired B cell Expression of the Inhibitory Fcgamma Receptor IIB in Myasthenia Gravis.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26507.
    >> Share

  20. GAUDIOSO CM, Mar S, Casper TC, Codden R, et al
    MOG and AQP4 antibodies among children with multiple sclerosis and controls.
    Ann Neurol. 2022 Sep 11. doi: 10.1002/ana.26502.
    >> Share

    August 2022
  21. LINDGREN U, Pullerits R, Lindberg C, Oldfors A, et al
    Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.
    Ann Neurol. 2022;92:201-212.
    >> Share

    June 2022
  22. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    >> Share

  23. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    >> Share

  24. KOIZUMI N, Takasugi J, Ohara N, Kawamoto M, et al
    FDG-PET/CT of Giant Cell Arteritis With Normal Inflammatory Markers.
    Ann Neurol. 2022 Jun 6. doi: 10.1002/ana.26428.
    >> Share

  25. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    >> Share

    May 2022
  26. CACCIAGUERRA L, Carotenuto A, Pagani E, Mistri D, et al
    Ann Neurol. 2022 May 20. doi: 10.1002/ana.26419.
    >> Share

  27. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    >> Share

  28. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    >> Share

  29. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    >> Share

    April 2022
  30. MANDEL-BREHM C, Benson LA, Tran B, Kung AF, et al
    ZSCAN1 autoantibodies are associated with pediatric paraneoplastic ROHHAD.
    Ann Neurol. 2022 Apr 25. doi: 10.1002/ana.26380.
    >> Share

  31. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    >> Share

  32. IWAMOTO S, Itokazu T, Sasaki A, Kataoka H, et al
    RGMa Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in NMO.
    Ann Neurol. 2022;91:532-547.
    >> Share

  33. DOETS AY, Walgaard C, Lingsma HF, Islam B, et al
    International Validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score.
    Ann Neurol. 2022;91:521-531.
    >> Share

    March 2022
  34. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    >> Share

  35. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    >> Share

  36. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    >> Share

  37. KORNEK B, Leutmezer F, Rommer PS, Koblischke M, et al
    B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.
    Ann Neurol. 2022;91:342-352.
    >> Share

    February 2022
  38. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    >> Share

  39. ZEKERIDOU A, Yang B, Lennon VA, Guo Y, et al
    Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26320.
    >> Share

  40. MCCOMBE JA, Flanagan EP, Chen JJ, Zekeridou A, et al
    Investigating the Immunopathogenic Mechanisms Underlying MOGAD.
    Ann Neurol. 2022;91:299-300.
    >> Share

    January 2022
  41. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    >> Share

    December 2021
  42. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    >> Share

  43. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    >> Share

  44. HEINE J, Kopp UA, Klag J, Ploner CJ, et al
    Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
    Ann Neurol. 2021;90:949-961.
    >> Share

  45. SANTYR B, Pejhan S, Zhang Q, Budhram A, et al
    Unilateral Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2021;90:999-1000.
    >> Share

    November 2021
  46. ZRZAVY T, Endmayr V, Bauer J, Macher S, et al
    Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.
    Ann Neurol. 2021;90:725-737.
    >> Share

  47. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    >> Share

    October 2021
  48. MARAMATTOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Reply to 'Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis by Dr Pegat et al.
    Ann Neurol. 2021 Oct 27. doi: 10.1002/ana.26257.
    >> Share

  49. PEGAT A, Vogrig A, Khouri C, Masmoudi K, et al
    Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis.
    Ann Neurol. 2021 Oct 26. doi: 10.1002/ana.26258.
    >> Share

  50. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    >> Share

    September 2021
  51. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    >> Share

  52. OSOWICKI J, Morgan H, Harris A, Crawford NW, et al
    Guillain-Barre Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines.
    Ann Neurol. 2021 Sep 15. doi: 10.1002/ana.26218.
    >> Share

  53. ZUHORN F, Graf T, Klingebiel R, Schabitz WR, et al
    Postvaccinal Encephalitis after ChAdOx1 nCov-19.
    Ann Neurol. 2021;90:506-511.
    >> Share

    August 2021
  54. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    >> Share

  55. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    >> Share

  56. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    >> Share

  57. TEWKESBURY G, Song JW, Perrone CM
    Magnetic Resonance Imaging of Autoimmune GFAP Astrocytopathy.
    Ann Neurol. 2021 Aug 13. doi: 10.1002/ana.26195.
    >> Share

    July 2021
  58. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
    Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
    >> Share

  59. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    >> Share

  60. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    >> Share

    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    >> Share

    June 2021
  62. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
    Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
    >> Share

  63. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
    >> Share

    Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
    Ann Neurol. 2021;89:1084-1087.
    >> Share

  65. WINGERCHUK DM, Fujihara K, Palace J, Berthele A, et al
    Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Ann Neurol. 2021;89:1088-1098.
    >> Share

    May 2021
  66. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    >> Share

  67. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
    Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
    Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
    >> Share

  68. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
    Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
    Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
    >> Share

  69. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    >> Share

    April 2021
  70. IZUKA S, Kobayashi T, Takahashi Y
    Tongue tremor in systemic lupus erythematosus.
    Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
    >> Share

  71. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    >> Share

    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    >> Share

  73. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    >> Share

  74. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    January 2021
  75. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016